Journal
JOURNAL OF GASTRIC CANCER
Volume 23, Issue 1, Pages 207-223Publisher
KOREAN GASTRIC CANCER ASSOC
DOI: 10.5230/jgc.2023.23.e10
Keywords
Gastric cancer; Immunotherapy; Immune checkpoint inhibitors; Chemotherapy; Biomarkers
Categories
Ask authors/readers for more resources
Gastric cancer is the fourth leading cause of cancer-related deaths globally. Immunotherapy has become an important therapeutic strategy in medical oncology, leading to changes in the treatment of gastric cancer. Immune checkpoint inhibitors have shown significant improvements in survival rates for gastric cancer patients. Further research is being conducted on combination therapies and subsequent treatments to enhance the application of immunotherapy in gastric cancer.
Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. Under the standard of care, patients with advanced GC (AGC) have a median survival time of approximately 12-15 months. With the emergence of immunotherapy as a key therapeutic strategy in medical oncology, relevant changes are expected in the systemic treatment of GC. In the phase III ATTRACTION-2 trial, nivolumab, a monoclonal anti-programmed cell death 1 (PD-1) antibody, as a third-or later-line treatment improved overall survival (OS) compared with placebo in patients with AGC. Furthermore, nivolumab in combination with 5-fluorouracil and platinum as a first-line treatment improved OS in patients with human epidermal growth factor receptor-2 (HER2)-negative AGC in the global phase III CheckMate-649 study. Another anti-PD-1 antibody, pembrolizumab, in combination with trastuzumab and cytotoxic chemotherapy as a first-line treatment, significantly improved the overall response rate in patients with HER2-positive AGC. Therefore, immune checkpoint inhibitors (ICIs) are essential components of the current treatment of GC. Subsequent treatments after ICI combination therapy, such as ICI rechallenge or combination therapy with agents having other modes of action, are being actively investigated to date. On the basis of the success of immunotherapy in the treatment of AGC, various clinical trials are underway to apply this therapeutic strategy in the perioperative and postoperative settings for patients with early GC. This review describes recent progress in immunotherapy and potential immunotherapy biomarkers for GC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available